Table 8. Analysis of subgroup of patients with urgent PCI.
| Parameters | All (n = 49) | Weekend group (n = 21) | Weekday group (n = 28) | P value |
|---|---|---|---|---|
| Reason for urgent PCI | 0.215 | |||
| Refractory angina | 28 (57.1%) | 15 (71.4%) | 13 (46.4%) | |
| Hemodynamic instability | 10 (20.4%) | 3 (14.3%) | 7 (25.0%) | |
| Electrical instability | 11 (22.4%) | 3 (14.3%) | 8 (28.6%) | |
| Time interval from reason to urgent PCI (min, median) | 118.8 ± 46.7 (109.0) | 107.4 ± 42.2 (95.0) | 127.4 ± 48.8 (119.0) | 0.139 |
| Age | 62.1 ± 12.5 | 59.9 ± 13.5 | 63.8 ± 11.7 | 0.287 |
| Sex (male) | 38 (77.6%) | 18 (85.7%) | 20 (71.4%) | 0.311 |
| Height (cm) | 163.9 ± 9.0 | 165.0 ± 8.3 | 163.1 ± 9.6 | 0.472 |
| Body weight (kg) | 64.6 ± 12.2 | 64.8 ± 12.1 | 64.4 ± 12.4 | 0.926 |
| Body mass index (kg/m2) | 23.9 ± 3.3 | 23.6 ± 3.1 | 24.0 ± 1.8 | 0.641 |
| Hypertension | 26 (53.1%) | 8 (38.1%) | 18 (64.3%) | 0.069 |
| Diabetes mellitus | 11 (22.4%) | 5 (23.8%) | 6 (21.4%) | 0.843 |
| Hyperlipidemia | 12 (24.5%) | 5 (23.8%) | 7 (25.0%) | 0.924 |
| Smoking, current | 16 (32.7%) | 7 (33.3%) | 9 (32.1%) | 0.930 |
| Previous myocardial infarction | 12 (24.5%) | 6 (28.6%) | 6 (21.4%) | 0.565 |
| Previous CABG | 2 (4.1%) | 1 (4.8%) | 1 (3.6%) | 1.000 |
| Hemoglobin, g/dL | 13.9 ± 2.0 | 13.6 ± 2.3 | 14.0 ± 1.8 | 0.509 |
| eGFR (mL/min/m2) | 63.0 ± 30.2 | 70.3 ± 36.1 | 57.7 ± 24.1 | 0.148 |
| Total cholesterol (mg/dL) | 200.5 ± 43.4 | 191.3 ± 41.6 | 207.3 ± 44.2 | 0.206 |
| Triglyceride (mg/dL) | 121.2 ± 84.5 | 143.4 ± 114.3 | 105.6 ± 52.0 | 0.137 |
| HDL-cholesterol (mg/dL) | 42.4 ± 7.2 | 41.4 ± 5.8 | 43.0 ± 8.1 | 0.485 |
| LDL-cholesterol (mg/dL) | 101.1 ± 36.7 | 100.4 ± 37.8 | 101.6 ± 36.8 | 0.918 |
| NT-proBNP (pg/mL) | 2,489.4 ± 6,157.8 | 1,560.2 ± 3,617.1 | 3,168.5 ± 7,495.4 | 0.393 |
| hsCRP (mg/dL) | 1.3 ± 3.4 | 2.4 ± 5.1 | 0.6 ± 0.6 | 0.128 |
| CK-MB elevation* | 26 (53.1%) | 9 (42.9%) | 17 (60.7%) | 0.215 |
| Troponin-I elevation* | 36 (73.5%) | 16 (76.2%) | 20 (71.4%) | 0.709 |
| Ischemic ECG change | 0.480 | |||
| ST depression | 19 (38.8%) | 10 (47.6%) | 9 (32.1%) | |
| T-wave inversion | 4 (8.2%) | 1 (4.8%) | 3 (10.7%) | |
| Echocardiographic LV EF (%) | 54.6 ± 10.3 | 55.9 ± 9.2 | 53.6 ± 11.3 | 0.502 |
| TIMI risk score | 0.409 | |||
| Low (0-2) | 17 (34.7%) | 6 (28.6%) | 11 (39.3%) | |
| Intermediate (3-4) | 26 (53.1%) | 11 (52.4%) | 15 (53.6%) | |
| High (5-7) | 6 (12.2%) | 4 (19.0%) | 2 (7.1%) | |
| Culprit artery | 0.310 | |||
| Left main coronary artery | 2 (4.1%) | 1 (4.8%) | 1 (3.6%) | |
| Left anterior descending artery | 23 (46.9%) | 10 (47.6%) | 13 (46.4%) | |
| Left circumflex artery | 13 (26.5%) | 8 (38.1%) | 5 (17.9%) | |
| Right coronary artery | 10 (20.4%) | 2 (9.5%) | 8 (28.6%) | |
| CAD extent | 0.607 | |||
| 1 vessel disease | 22 (44.9%) | 8 (38.1%) | 14 (50.0%) | |
| 2 vessel disease | 11 (22.4%) | 6 (28.6%) | 5 (17.9%) | |
| 3 vessel disease | 16 (32.7%) | 7 (33.3%) | 9 (32.1%) | |
| Symptom-to-admission time (hr, median) | 37.3 ± 116.2 (5.5) | 32.2 ± 103.3 (5.2) | 41.1 ± 126.8 (6.0) | 0.793 |
| Admission-to-PCI time (hr, median) | 7.6 ± 7.6 (4.8) | 7.2 ± 8.6 (4.4) | 7.9 ± 7.0 (6.6) | 0.742 |
| Concomitant medications | ||||
| Heparin | 43 (87.8%) | 19 (90.5%) | 24 (85.7%) | 0.688 |
| GpIIb/IIIa R antagonists | 17 (34.7%) | 8 (38.1%) | 9 (32.1%) | 0.665 |
| Tirofiban | 2 (4.1%) | 0 (0.0%) | 2 (7.1%) | 0.500 |
| Abciximab | 15 (30.6%) | 8 (38.1%) | 7 (25.0%) | 0.325 |
| Aspirin | 49 (100%) | 21 (100%) | 28 (100%) | 1.000 |
| Clopidogrel | 49 (100%) | 21 (100%) | 28 (100%) | 1.000 |
| Beta-blocker | 32 (65.3%) | 17 (81.0%) | 15 (53.6%) | 0.070 |
| ACEI/ARB | 33 (67.3%) | 17 (81.0%) | 16 (57.1%) | 0.079 |
| Statin | 37 (75.5%) | 15 (71.4%) | 22 (78.6%) | 0.565 |
*>1×upper reference limit; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT-proBNP, N-terminal-proB-type natriuretic peptide; hsCRP, high-sensitivity C-reactive protein; CK-MB, creatine kinase-myocardial band; ECG, electrocardiography; LV EF, left ventricle ejection fraction; TIMI, thrombolysis in myocardial infarction; CAD, coronary artery disease; GpIIb/IIIa R, glycoprotein IIb/IIIa receptor; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker.